Chiltern seeking metabolism expertise for new unit after hiring ex PPD exec
Chiltern’s acquisition of Theorem last month strengthened its oncology, biopharma, medical device and diagnostic offerings, creating what the firm said is the largest mid-sized contract research organisation (CRO).
Now the firm says it is expanding its business further to include endocrine and metabolism services through the addition of Randy Anderson as senior vice president of scientific affairs.
“My experience and expertise in strategic program design for endocrine and metabolism products will be a new service offering at Chiltern,” Anderson, who has nearly 30 years of industry experience in the industry, told Outsourcing-Pharma.
“My hire is synergistic with the recent Theorem acquisition in expanding Chiltern’s capacity for design and execution of endocrinology and metabolism programs.”
For the past five years, Anderson served as Vice President of Global Product Development for Metabolics at PPD, and before that spent twelve years at the Big CRO in senior management roles.
He is now looking to help Chiltern respond to client demand by expanding its clinical services for endocrinology and metabolism, and said the firm is looking for further expertise:
“Chiltern is actively hiring management and operations staff with experience in endocrinology and metabolism indications,” he told us.
This include: “Type 2 diabetes, type 1 diabetes, diabetes complications, nonalcoholic steatohepatitis, obesity, dyslipidemias, adrenal disorders, thyroid disorders, pituitary disorders, calcium homeostasis disorders, cardiovascular disease prevention, growth disorders, sex androgen dysfunction and other rare metabolic disease indications such as lysosomal storage disorders, Prader-Willi Syndrome and Fabry disease.”
